In the earnings call that followed on November 7th, Forescout president and CEO Michael DeCesare tried to blame the bad results on extended sales, but it didn’t really help, as private equity firms swooped in to make the deal. “We experienced extended sales cycles across several of our customers that pushed out deals and which did not become apparent until we entered the final days of the quarter. We do not believe that any of these deals have been lost to competitors,” he told analysts.
Today, on Twist’s quarterly earnings call, the company also reported that its revenue increased 49.3% year-over-year to $17.2 million. Twist forecast revenue exceeding $80 million for 2020. On Thursday morning, shares of Twist Bioscience (NASDAQ: TWST) were trading at just below $27. By Friday afternoon, they were just above $32 a share, a rise of more than 18%, bringing its market capitalization to $1.1 billion.